Forte Biosciences, Inc. (FBRX) |
| 15.27 0.13 (0.86%) 10-10 16:00 |
| Open: | 15.15 |
| High: | 15.27 |
| Low: | 14.5 |
| Volume: | 75,938 |
| Market Cap: | 190(M) |
| PE Ratio: | -4.15 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 19.85 |
| Resistance 1: | 17.00 |
| Pivot price: | 14.67 |
| Support 1: | 12.74 |
| Support 2: | 10.11 |
| 52w High: | 28.68 |
| 52w Low: | 4.11 |
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
Financials
| EPS | -3.680 |
| Book Value | 8.030 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -40.8 |
| Return on Equity (ttm) | -73.5 |
Company news
Mon, 06 Oct 2025
Forte Biosciences Inc. Reports Inducement Grants Under Nasdaq Listing Rules - MarketScreener
Thu, 02 Oct 2025
Forte Biosciences Sees Unusually High Options Volume (NASDAQ:FBRX) - MarketBeat
Sun, 21 Sep 2025
Investors Purchase High Volume of Call Options on Forte Biosciences (NASDAQ:FBRX) - MarketBeat
Wed, 17 Sep 2025
Forte Biosciences Reaches US$205m Market Cap Benefiting Insider Stock Buying - simplywall.st
Sun, 03 Aug 2025
Forte Biosciences, Inc.'s (NASDAQ:FBRX) recent 17% pullback adds to one-year year losses, institutional owners may take drastic measures - simplywall.st
Wed, 25 Jun 2025
Forte Biosciences Announces Pricing of $75 Million Public Offering - FinancialContent
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
